Mario Sznol's guest appearances

Mario Sznol

Dermatologic Oncology Update

Research To Practice | Oncology Videos

 2013 ASCO Annual Meeting

Thomas Budd

Keith T Flaherty

Jedd D Wolchok

Jeffrey Weber

Adil Daud

Jeffery Weber

Evan J Lipson

Antoni Ribas

Omid Hamid

Rene Gonzalez

Kim Margolin

Karl Lewis

Dirk Schadendorf

John M Kirkwood

Aleksandar Sekulic

OwlTail

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Mario Sznol, MD conducted by Neil Love, MD. Produced by Research To Practice

DOU 1 2019 | Interview with Mario Sznol, MD

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Mario Sznol, MD conducted by Neil Love, MD. Produced by Research To Practice.

DOU1 2014 | Interview with Mario Sznol, MD

Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma.107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard systemic therapies — 25 percent had three or more prior therapies and 63 percent had two or more. Overall, 33 out of 107 (31 percent) of patients experienced tumor shrinkage of at least 30 percent and responses were seen at all doses. The estimate for survival at two years was 43 percent. The median overall survival across all doses was 16.8 months; 20.3 months for the dose chosen for study in subsequent clinical trials.

Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma.<br><br>107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard systemic therapies — 25 percent had three or more prior therapies and 63 percent had two or more. Overall, 33 out of 107 (31 percent) of patients experienced tumor shrinkage of at least 30 percent and responses were seen at all doses. The estimate for survival at two years was 43 percent. The median overall survival across all doses was 16.8 months; 20.3 months for the dose chosen for study in subsequent clinical trials.

Nivolumab produces long-lasting responses in patients with stage IV melanoma: Dr Mario Sznol